Compare Bristol-Myers Squibb Co (BMY) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Warner Music Group Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.79 (market cap $116.30B), while Warner Music Group Corp trades at $28.3 (market cap $14.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.1× Warner Music Group Corp's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | WMG | |
|---|---|---|
Market Cap | $116.30B | $14.38B |
Sector | Health | Media |
52-Week High | $62.37 | $34.72 |
52-Week Low | $42.60 | $23.65 |
Enterprise Value | $152.24B | $18.58B |
Dividend Yield | 4.42% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Warner Music Group (WMG) trades at $28.75, down 0.83% today, with a bullish technical signal and strong analyst consensus. Recent financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. The company maintains solid profitability with a 45.8% gross margin and recently acquired AI startup Sureel AI to enhance intellectual property management. Cash flow from operations remains healthy at $678M despite a net cash outflow of $159M in 2025.
WMG offers upside with a $40.40 consensus price target (40.5% potential) and 66.7% buy ratings, supported by streaming growth and AI initiatives. Risks include competitive pressures, margin volatility, and reliance on music industry trends. The stock's high P/E of 34.23 requires sustained earnings acceleration to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
